John Weidenbruch

John Weidenbruch is Epizyme’s General Counsel. With three decades of legal affairs and policy experience, John has served as General Counsel for some of the world’s leading pharmaceutical and biotech organizations, including Biogen, Inc., Idenix Pharmaceuticals, Abraxis BioScience, Amgen, and, most recently, Visterra, Inc. John began his career in healthcare policy as a lobbyist for the Consumer Healthcare Products Association (CHPA), formerly known as the Non-Prescription Drug Manufacturer Association.

John graduated with a BS in Sociology from Loyola University in Maryland and earned a JD from Georgetown University Law Center. An alumnus of the board of trustees, John served as a board member of the American Kidney Fund for seven years.